Asset profile
enlicitide · Merck (MRK)
- Indication
- hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH)
- Also known as
- LIPFENDRA, enlicitide, Lipfendra
Company
MRKMerck
MRKMerckMerck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sale…
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT06450366 | Phase 3 | Completed | Feb 14, 2025 | 301 | 7 of 35 sites in the United States |
| NCT05952856 | Phase 3 | Completed | Jul 28, 2025 | 2912 | 49 of 168 sites in the United States |
| NCT06008756 | Phase 3 | Active, not recruiting | Nov 29, 2029 | 14550 | 132 of 669 sites in the United States |
| NCT07058077 | Phase 2/3 | Recruiting | Dec 4, 2033 | 153 | 8 of 47 sites in the United States |
| NCT05952869 | Phase 3 | Completed | Apr 7, 2025 | 303 | 13 of 59 sites in the United States |
| NCT06492291 | Phase 3 | Active, not recruiting | Oct 13, 2028 | 3000 | 52 of 222 sites in the United States |
| NCT07614984 | Phase 2 | Recruiting | Oct 12, 2027 | 750 | 24 of 76 sites in the United States |
More from Merck
Other drugs and candidates from the same company tracked in this sector.
[212Pb]PSV359locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumorsalimatravirHIV-1 pre-exposure prophylaxisbelzutifanadvanced renal cell carcinoma with a clear cell component (ccRCC) following a PD-1 or PD-L1 inhibitorcalderasibfirst-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C-mutation and expressing PD-L1 (TPS ≥1%)clesrovimab-cforPrevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV seasonEIK1001first-line stage 4 non-small cell lung cancer (NSCLC)fluralanertreatment and control of Asian longhorned tick (Haemaphysalis longicornis) and Gulf Coast tick (Amblyomma maculatum) for 12 months in dogsIDVYNSOHIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirineintismeran autogeneadjuvant treatment for completely resected stage IIB-IV melanomaislatravir/lenacapavirHIV-1 treatment (virologically suppressed adults)olomorasibfirst-line KRAS G12C-mutant non-small cell lung cancerPDS0101HPV16-positive recurrent/metastatic head and neck squamous cell carcinomapembrolizumabmismatch repair deficient (dMMR) advanced or recurrent endometrial cancerpetosemtamabfirst-line PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)Pneumococcal 21-valent Conjugate VaccineActive immunization for the prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B in individuals 2 through 17 years of age who are at increased risk for pneumococcal diseaseremigromigdiabetic macular edema (DME)sacituzumab govitecan-hziyunresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and who are not candidates for PD-1 or PD-L1 inhibitor therapysacituzumab tirumotecanadvanced or recurrent endometrial cancersotatercept-csrkpulmonary arterial hypertension (PAH, WHO Group 1)SPR2015KRAS G12D-mutant tumors (pancreatic, colorectal, lung, and other cancers)tulisokibartmoderate to severe hidradenitis suppurativa (HS)VENTANA MMR RxDx PaneldMMR and pMMR solid tumors (colorectal, endometrial, gastric, small intestine, biliary)zanzalintinibpreviously treated metastatic colorectal cancer (CRC)